FDA finally approves Amylin's once-a-week diabetes injection

Share this article:

The third time was the charm for Amylin Pharmaceuticals' once-a-week diabetes injection drug. Bydureon was approved Friday, following two prior rejections. Amylin executives say the new drug's convenient regimen will give it a competitive advantage in the marketplace. Diabetes affects more than 25 million people in the U.S., including many nursing facility residents.


Share this article:

More in Products

LeadingAge's CAST releases medication management tools

LeadingAge's Center for Aging Services Technologies release new tools last week to help long-term care providers identify the best medication management product.

Butler Mobility updates paint colors for platform lifts

Butler Mobility updates paint colors for platform lifts

Butler Mobility has widened the spectrum of paint color choices for its Incline Platform Lifts line.

NeuroMetrix releases pain management system

NeuroMetrix releases pain management system

NeuroMetrix Inc. has created the SENSUS™ Pain Management System, a wearable neurostimulation technology developed for chronic neuropathic pain, including painful diabetic neuropathy.